Braveheart Bio
Tracked across 2 events · 31 articles · First seen Jul 06, 2026 · Last active Aug 06, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Braveheart Bio, a clinical-stage biopharmaceutical company developing therapies for hypertrophic cardiomyopathy, announced the pricing of its upsized initial public offering of 21,250,000 shares at $18.00 per share, expected to raise gross proceeds of $382.5 million.…
Impact: Braveheart Bio is the issuer of the IPO, raising $382.5 million in gross proceeds to fund development of its lead candidate BHB-1893. The successful pricing and expected listing on Nasdaq provide the company with capital and public market access.
Aug 06, 2026 · 6 articles
Business
Impact: Braveheart Bio is among biotechs queuing to list, potentially benefiting from the positive IPO climate.
Jul 06, 2026 · 25 articles
100
Braveheart Bio priced IPOBraveheart Bio upsized IPO pricing
50
United States — United States Securities and Exchange Commission declared effective Braveheart BioBraveheart Bio upsized IPO pricing
40
Braveheart Bio granted optionBraveheart Bio upsized IPO pricing
ERGEN INTELLIGENCE
Track Braveheart Bio live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard